Techno Drugs (TECHNODRUG) 주식 개요는 방글라데시 및 국제적으로 인체용 및 동물용 의약품을 제조 및 판매합니다. 자세히 보기TECHNODRUG 펀더멘털 분석스노우플레이크 점수가치 평가1/6미래 성장0/6과거 실적1/6재무 건전성2/6배당2/6위험 분석지난 5년간 매년 수익이 21.4% 감소했습니다.이자 지급액이 수익으로 잘 충당되지 않음2.11% 의 배당금은 잉여현금흐름으로 잘 충당되지 않습니다.지난 3개월 동안 주가 변동성이 BD 시장과 비교해 높았습니다.+ 위험 1건 추가모든 위험 점검 보기TECHNODRUG Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW484,317 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA484,317 investors already sharing narrativesYour Fair Value৳Current Price৳47.3086.2% 고평가 내재 할인율Growth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture03b2016201920222025202620282031Revenue ৳3.1bEarnings ৳202.4mAdvancedSet Fair ValueView all narrativesTechno Drugs Ltd. 경쟁사Orion InfusionSymbol: DSE:ORIONINFUMarket cap: ৳5.9bNavana PharmaceuticalsSymbol: DSE:NAVANAPHARMarket cap: ৳7.6bIBN SINA Pharmaceutical IndustrySymbol: DSE:IBNSINAMarket cap: ৳10.1bSilco PharmaceuticalsSymbol: DSE:SILCOPHLMarket cap: ৳2.2b가격 이력 및 성과Techno Drugs 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가৳47.3052주 최고가৳52.0052주 최저가৳25.20베타0.351개월 변동9.49%3개월 변동31.39%1년 변동44.65%3년 변동n/a5년 변동n/aIPO 이후 변동79.17%최근 뉴스 및 업데이트Valuation Update With 7 Day Price Move • Jul 20Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ৳50.00, the stock trades at a trailing P/E ratio of 32.6x. Average trailing P/E is 19x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 59% over the past year.Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 5 non-independent directors. Independent Director SK. Rahman was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공고 • Apr 27Techno Drugs Ltd. to Report Q3, 2026 Results on Apr 29, 2026Techno Drugs Ltd. announced that they will report Q3, 2026 results on Apr 29, 2026공고 • Jan 29Techno Drugs Ltd. to Report Q2, 2026 Results on Jan 31, 2026Techno Drugs Ltd. announced that they will report Q2, 2026 results on Jan 31, 2026공고 • Nov 09Techno Drugs Ltd. to Report Q1, 2026 Results on Nov 13, 2025Techno Drugs Ltd. announced that they will report Q1, 2026 results on Nov 13, 2025공고 • Oct 30Techno Drugs Ltd. announces Annual dividend, payable on January 25, 2026Techno Drugs Ltd. announced Annual dividend of BDT 1.0000 per share payable on January 25, 2026, ex-date on November 20, 2025 and record date on November 19, 2025.더 많은 업데이트 보기Recent updatesValuation Update With 7 Day Price Move • Jul 20Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ৳50.00, the stock trades at a trailing P/E ratio of 32.6x. Average trailing P/E is 19x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 59% over the past year.Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 5 non-independent directors. Independent Director SK. Rahman was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공고 • Apr 27Techno Drugs Ltd. to Report Q3, 2026 Results on Apr 29, 2026Techno Drugs Ltd. announced that they will report Q3, 2026 results on Apr 29, 2026공고 • Jan 29Techno Drugs Ltd. to Report Q2, 2026 Results on Jan 31, 2026Techno Drugs Ltd. announced that they will report Q2, 2026 results on Jan 31, 2026공고 • Nov 09Techno Drugs Ltd. to Report Q1, 2026 Results on Nov 13, 2025Techno Drugs Ltd. announced that they will report Q1, 2026 results on Nov 13, 2025공고 • Oct 30Techno Drugs Ltd. announces Annual dividend, payable on January 25, 2026Techno Drugs Ltd. announced Annual dividend of BDT 1.0000 per share payable on January 25, 2026, ex-date on November 20, 2025 and record date on November 19, 2025.공고 • Oct 29Techno Drugs Ltd., Annual General Meeting, Dec 24, 2025Techno Drugs Ltd., Annual General Meeting, Dec 24, 2025, at 10:00 Central Asia Standard Time. Location: hybrid system in combination of physical, presence at institution of diploma engineers, l60/a, kakrail vip road, through the link., Bangladesh공고 • Oct 21Techno Drugs Ltd. to Report Fiscal Year 2025 Results on Oct 28, 2025Techno Drugs Ltd. announced that they will report fiscal year 2025 results on Oct 28, 2025공고 • Apr 23Techno Drugs Ltd. to Report Q3, 2025 Results on Apr 29, 2025Techno Drugs Ltd. announced that they will report Q3, 2025 results on Apr 29, 2025공고 • Jan 27Techno Drugs Ltd. to Report Q2, 2025 Results on Jan 30, 2025Techno Drugs Ltd. announced that they will report Q2, 2025 results on Jan 30, 2025공고 • Nov 11Techno Drugs Ltd. to Report Q1, 2025 Results on Nov 14, 2024Techno Drugs Ltd. announced that they will report Q1, 2025 results on Nov 14, 2024공고 • Oct 29Techno Drugs Ltd. Recommends 12% Cash Dividend for the year ended June 30, 2024The Board of Directors of Techno Drugs Ltd. recommended 12% Cash Dividend only for general shareholders other than Board of Directors for the year ended June 30, 2024. Directors/sponsor are holding 82,776,200 shares and General Public are holding 49,221,988 shares. Cash dividend payable to General Public is Tk. 59,066,386.00. Date of AGM: December 26, 2024.Valuation Update With 7 Day Price Move • Oct 24Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ৳38.00, the stock trades at a trailing P/E ratio of 25.3x. Average trailing P/E is 18x in the Pharmaceuticals industry in Bangladesh.공고 • Oct 22Techno Drugs Ltd. to Report Fiscal Year 2024 Results on Oct 27, 2024Techno Drugs Ltd. announced that they will report fiscal year 2024 results on Oct 27, 2024New Risk • Sep 27New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended June 2023. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported June 2023 fiscal period end). Interest payments are not well covered by earnings (2.0x net interest cover). Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue has declined by 46% over the past year. Minor Risk Market cap is less than US$100m (৳5.87b market cap, or US$49.0m).Valuation Update With 7 Day Price Move • Sep 08Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to ৳40.50, the stock trades at a trailing P/E ratio of 27x. Average trailing P/E is 24x in the Pharmaceuticals industry in Bangladesh.Board Change • Jul 14Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 5 non-independent directors. Independent Director SK. Rahman was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.주주 수익률TECHNODRUGBD PharmaceuticalsBD 시장7D0.9%-2.5%-1.7%1Y44.6%5.3%0.2%전체 주주 수익률 보기수익률 대 산업: TECHNODRUG은 지난 1년 동안 5.3%의 수익을 기록한 BD Pharmaceuticals 산업보다 더 좋은 성과를 냈습니다.수익률 대 시장: TECHNODRUG은 지난 1년 동안 0.2%를 기록한 BD 시장보다 더 좋은 성과를 냈습니다.주가 변동성Is TECHNODRUG's price volatile compared to industry and market?TECHNODRUG volatilityTECHNODRUG Average Weekly Movement5.9%Pharmaceuticals Industry Average Movement4.4%Market Average Movement4.8%10% most volatile stocks in BD Market7.4%10% least volatile stocks in BD Market2.9%안정적인 주가: TECHNODRUG의 주가는 지난 3개월 동안 BD 시장보다 변동성이 컸습니다.시간에 따른 변동성: TECHNODRUG의 주간 변동성(6%)은 지난 1년 동안 안정적이었지만 BD 종목 중 상위 75%보다 높습니다.회사 소개설립직원 수CEO웹사이트20091,438Shah Jalal Ahmedwww.technodrugsltd.com는 방글라데시 및 국제적으로 인체용 및 동물용 의약품을 제조 및 판매합니다. 또한 종양학 의약품도 제공합니다. 이 회사는 2009년에 설립되었으며 방글라데시 다카에 본사를 두고 있습니다.더 보기Techno Drugs Ltd. 기초 지표 요약Techno Drugs의 순이익과 매출은 시가총액과 어떻게 비교됩니까?TECHNODRUG 기초 통계시가총액৳6.24b순이익 (TTM)৳202.41m매출 (TTM)৳3.10b30.8x주가수익비율(P/E)2.0x주가매출비율(P/S)TECHNODRUG는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표TECHNODRUG 손익계산서 (TTM)매출৳3.10b매출원가৳1.75b총이익৳1.35b기타 비용৳1.15b순이익৳202.41m최근 보고된 실적Mar 31, 2026다음 실적 발표일해당 없음주당순이익(EPS)1.53총이익률43.66%순이익률6.53%부채/자본 비율66.7%TECHNODRUG의 장기 실적은 어땠습니까?과거 실적 및 비교 보기배당2.1%현재 배당 수익률62%배당 성향View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/25 06:56종가2026/07/23 00:00수익2026/03/31연간 수익2025/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Techno Drugs Ltd.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Valuation Update With 7 Day Price Move • Jul 20Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ৳50.00, the stock trades at a trailing P/E ratio of 32.6x. Average trailing P/E is 19x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 59% over the past year.
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 5 non-independent directors. Independent Director SK. Rahman was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공고 • Apr 27Techno Drugs Ltd. to Report Q3, 2026 Results on Apr 29, 2026Techno Drugs Ltd. announced that they will report Q3, 2026 results on Apr 29, 2026
공고 • Jan 29Techno Drugs Ltd. to Report Q2, 2026 Results on Jan 31, 2026Techno Drugs Ltd. announced that they will report Q2, 2026 results on Jan 31, 2026
공고 • Nov 09Techno Drugs Ltd. to Report Q1, 2026 Results on Nov 13, 2025Techno Drugs Ltd. announced that they will report Q1, 2026 results on Nov 13, 2025
공고 • Oct 30Techno Drugs Ltd. announces Annual dividend, payable on January 25, 2026Techno Drugs Ltd. announced Annual dividend of BDT 1.0000 per share payable on January 25, 2026, ex-date on November 20, 2025 and record date on November 19, 2025.
Valuation Update With 7 Day Price Move • Jul 20Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ৳50.00, the stock trades at a trailing P/E ratio of 32.6x. Average trailing P/E is 19x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 59% over the past year.
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 5 non-independent directors. Independent Director SK. Rahman was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공고 • Apr 27Techno Drugs Ltd. to Report Q3, 2026 Results on Apr 29, 2026Techno Drugs Ltd. announced that they will report Q3, 2026 results on Apr 29, 2026
공고 • Jan 29Techno Drugs Ltd. to Report Q2, 2026 Results on Jan 31, 2026Techno Drugs Ltd. announced that they will report Q2, 2026 results on Jan 31, 2026
공고 • Nov 09Techno Drugs Ltd. to Report Q1, 2026 Results on Nov 13, 2025Techno Drugs Ltd. announced that they will report Q1, 2026 results on Nov 13, 2025
공고 • Oct 30Techno Drugs Ltd. announces Annual dividend, payable on January 25, 2026Techno Drugs Ltd. announced Annual dividend of BDT 1.0000 per share payable on January 25, 2026, ex-date on November 20, 2025 and record date on November 19, 2025.
공고 • Oct 29Techno Drugs Ltd., Annual General Meeting, Dec 24, 2025Techno Drugs Ltd., Annual General Meeting, Dec 24, 2025, at 10:00 Central Asia Standard Time. Location: hybrid system in combination of physical, presence at institution of diploma engineers, l60/a, kakrail vip road, through the link., Bangladesh
공고 • Oct 21Techno Drugs Ltd. to Report Fiscal Year 2025 Results on Oct 28, 2025Techno Drugs Ltd. announced that they will report fiscal year 2025 results on Oct 28, 2025
공고 • Apr 23Techno Drugs Ltd. to Report Q3, 2025 Results on Apr 29, 2025Techno Drugs Ltd. announced that they will report Q3, 2025 results on Apr 29, 2025
공고 • Jan 27Techno Drugs Ltd. to Report Q2, 2025 Results on Jan 30, 2025Techno Drugs Ltd. announced that they will report Q2, 2025 results on Jan 30, 2025
공고 • Nov 11Techno Drugs Ltd. to Report Q1, 2025 Results on Nov 14, 2024Techno Drugs Ltd. announced that they will report Q1, 2025 results on Nov 14, 2024
공고 • Oct 29Techno Drugs Ltd. Recommends 12% Cash Dividend for the year ended June 30, 2024The Board of Directors of Techno Drugs Ltd. recommended 12% Cash Dividend only for general shareholders other than Board of Directors for the year ended June 30, 2024. Directors/sponsor are holding 82,776,200 shares and General Public are holding 49,221,988 shares. Cash dividend payable to General Public is Tk. 59,066,386.00. Date of AGM: December 26, 2024.
Valuation Update With 7 Day Price Move • Oct 24Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ৳38.00, the stock trades at a trailing P/E ratio of 25.3x. Average trailing P/E is 18x in the Pharmaceuticals industry in Bangladesh.
공고 • Oct 22Techno Drugs Ltd. to Report Fiscal Year 2024 Results on Oct 27, 2024Techno Drugs Ltd. announced that they will report fiscal year 2024 results on Oct 27, 2024
New Risk • Sep 27New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended June 2023. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported June 2023 fiscal period end). Interest payments are not well covered by earnings (2.0x net interest cover). Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue has declined by 46% over the past year. Minor Risk Market cap is less than US$100m (৳5.87b market cap, or US$49.0m).
Valuation Update With 7 Day Price Move • Sep 08Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to ৳40.50, the stock trades at a trailing P/E ratio of 27x. Average trailing P/E is 24x in the Pharmaceuticals industry in Bangladesh.
Board Change • Jul 14Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 5 non-independent directors. Independent Director SK. Rahman was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
